To include your compound in the COVID-19 Resource Center, submit it here.

Clover: trimerizing fusion proteins

Chengdu-based Clover is targeting cancer and infectious disease pathways that depend on trimer formation

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation.

The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by Sichuan Clover Biopharmaceuticals Inc. co-founder, President and Chairman Peng Liang.

Clover’s other co-founders are Xiaodong Wang and Jianwei Zhu. Wang co-founded BeiGene Ltd. (NASDAQ:BGNE) in 2010 and chairs its scientific advisory board, and has served as founding director of China’s National Institute of Biological Sciences

Read the full 795 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE